Md Shahed-Morshed

Dr. Md Shahed-Morshed


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2025 in Clinical and Experimental Reproductive Medicine
Verified
Journal Article
Open access
PDF file
Md Shahed-MorshedMd Shahed-Morshed
Md Shahed-Morshed
HBHurjahan Banu
Hurjahan Banu
SHShamim Hossan
Shamim Hossan
HMHafsa Mahrukh
Hafsa Mahrukh
MHMuhammad Abul Hasanat
Muhammad Abul Hasanat
Objective: We compared various adiposity indices (AIs)—body mass index (BMI), waist circumference (WC), visceral adiposity index (VAI), lipid accumulation product, and the triglyceride-glucose (TyG), TyG-BMI, and TyG-WC indices—regarding their associations with insulin resistance (IR) among women with polycystic ovary syndrome (PCOS).Methods: This cross-sectional investigation included 632 reproductive-aged women with PCOS, aligning with the 2018 International Evidence-based Guideline. Clinical characteristics, including height, weight, and WC, were recorded. Fasting blood samples were analyzed to measure insulin, lipid, and glucose levels. AIs were then calculated using these measurements along with various formulas. The homeostatic model assessment for IR was utilized, with a value of 2.6 or higher indicating IR. An area under the curve (AUC) above 0.8 was considered clinically useful.Results: Approximately 69.1% of participants exhibited IR. All AIs were significant predictors of IR, regardless of androgen status. VAI and the TyG index were identified as poor markers of IR among women with PCOS (AUC, 0.6 to 0.69), while the remaining indices were considered fair markers (AUC, 0.7 to 0.79). VAI underperformed all other AIs except the TyG index, which was notably inferior to the TyG-BMI and TyG-WC indices. Nevertheless, the AUCs of TyG-BMI and TyG-WC were similar to those of BMI and WC.Conclusion: Although AIs exhibit androgen-independent relationships with IR, their usefulness as indicators of IR in PCOS is not adequately supported by our results (AUC <0.8). Furthermore, combining the TyG index with BMI and WC does not significantly improve the diagnostic utility of IR.

1 October 2019 in Endocrinology, Diabetes & Metabolism Case Reports
Verified
Journal Article
Open access
PDF file
SJSharmin Jahan
Sharmin Jahan
MHM A Hasanat
M A Hasanat
TMTahseen Mahmood
Tahseen Mahmood
Md Shahed-MorshedMd Shahed-Morshed
Md Shahed-Morshed
RHRaziul Haq
Raziul Haq
MFMd Fariduddin
Md Fariduddin
Summary Silent corticotroph adenoma (SCA) is an unusual type of nonfunctioning pituitary adenoma (NFA) that is silent both clinically and biochemically and can only be recognized by positive immunostaining for ACTH. Under rare circumstances, it can transform into hormonally active disease presenting with severe Cushing syndrome. It might often produce diagnostic dilemma with difficult management issue if not thoroughly investigated and subtyped accordingly following surgery. Here, we present a 21-year-old male who initially underwent pituitary adenomectomy for presumed NFA with compressive symptoms. However, he developed recurrent and invasive macroadenoma with severe clinical as well as biochemical hypercortisolism during post-surgical follow-up. Repeat pituitary surgery was carried out urgently as there was significant optic chiasmal compression. Immunohistochemical analysis of the tumor tissue obtained on repeat surgery proved it to be an aggressive corticotroph adenoma. Though not cured, he showed marked clinical and biochemical improvement in the immediate postoperative period. Anticipating recurrence from the residual tumor, we referred him for cyber knife radio surgery. Learning points: Pituitary NFA commonly present with compressive symptoms such as headache and blurred vision. Post-surgical development of Cushing syndrome in such a case could be either drug induced or endogenous. In the presence of recurrent pituitary tumor, ACTH-dependent Cushing syndrome indicates CD. Rarely a SCA presenting initially as NFA can transform into an active corticotroph adenoma. Immunohistochemical marker for ACTH in the resected tumor confirms the diagnosis. Abstract Summary Silent corticotroph adenoma (SCA) is an unusual type of nonfunctioning pituitary adenoma (NFA) that is silent both clinically and biochemically and can only be recognized by positive immunostaining for ACTH. Under rare circumstances, it can transform into hormonally active disease presenting with severe Cushing syndrome. It might often produce diagnostic dilemma with difficult management issue if not thoroughly investigated and subtyped accordingly following surgery. Here, we present a 21-year-old male who initially underwent pituitary adenomectomy for presumed NFA with compressive symptoms. However, he developed recurrent and invasive macroadenoma with severe clinical as well as biochemical hypercortisolism during post-surgical follow-up. Repeat pituitary surgery was carried out urgently as there was significant optic chiasmal compression. Immunohistochemical analysis of the tumor tissue obtained on repeat surgery proved it to be an aggressive corticotroph adenoma. Though not cured, he showed marked clinical and biochemical improvement in the immediate postoperative period. Anticipating recurrence from the residual tumor, we referred him for cyber knife radio surgery. Learning points: Pituitary NFA commonly present with compressive symptoms such as headache and blurred vision. Post-surgical development of Cushing syndrome in such a case could be either drug induced or endogenous. In the presence of recurrent pituitary tumor, ACTH-dependent Cushing syndrome indicates CD. Rarely a SCA presenting initially as NFA can transform into an active corticotroph adenoma. Immunohistochemical marker for ACTH in the resected tumor confirms the diagnosis.

1 August 2020 in medRxiv
Verified
Preprint
Open access
PDF file
Md Shahed-MorshedMd Shahed-Morshed
Md Shahed-Morshed
AMAbdullah Al Mosabbir
Abdullah Al Mosabbir
PCProdipta Chowdhury
Prodipta Chowdhury
SASheikh Mohammad Ashadullah
Sheikh Mohammad Ashadullah
MHMohammad Sorowar Hossain
Mohammad Sorowar Hossain
Bangladesh is in the rising phase of the ongoing pandemic of the coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The scientific literature on clinical manifestations of COVID-19 patients from Bangladesh is scarce. This study aimed to report the sociodemographic and clinical characteristics of patients with COVID-19 in Bangladesh. We conducted a cross-sectional study at three dedicated COVID-19 hospitals. The severity of the COVID-19 cases was assessed based on the WHO interim guidance. Data were collected only from non-critical COVID-19 patients as critical patients required immediate intensive care admission making them unable to respond to the questions. A total of 103 RT-PCR confirmed non-critical COVID-19 patients were enrolled. Most of the patients (71.8%) were male. Mild, moderate and severe illness were assessed in 74.76%, 9.71% and 15.53% of patients respectively. Nearly 52.4% of patients had a co-morbidity, with hypertension being the most common (34%), followed by diabetes mellitus (21.4%) and ischemic heart disease (9.7%). Fever (78.6%), weakness (68%) and cough (44.7%) were the most common clinical manifestations. Other common symptoms included loss of appetite (37.9%), difficulty in breathing (37.9%), altered sensation of taste or smell (35.0%), headache (32%) and body ache (32%). The median time from onset of symptom to attending hospitals was 7 days (IQR 4-10). This study will help both the clinicians and epidemiologists to understand the magnitude and clinical spectrum of COVID-19 patients in Bangladesh.

25 August 2021 in IMC Journal of Medical Science
Verified
Journal Article
Open access
PDF file
NANazma Akhtar
Nazma Akhtar
HBHurjahan Banu
Hurjahan Banu
Md Shahed-MorshedMd Shahed-Morshed
Md Shahed-Morshed
TSTania Sultana
Tania Sultana
ABAfroza Begum
Afroza Begum
MHMa Hasanat
Ma Hasanat
Background and objectives: Metformin improves manifestations of polycystic ovary syndrome (PCOS) by reducing insulin resistance. The objective of this study was to determine how metformin, in combination with lifestyle changes, affects the clinical manifestations of PCOS. Materials and Methods: Patients with PCOS attending the outpatient of a tertiary care hospital were enrolled in the study. Revised Rotterdam Consensus 2003 criteria were used to diagnose cases of PCOS. Clinical information, anthropometric measurement, serum progesterone and polycystic ovarian morphology (PCOM) of each subject were recorded in a prescribed data sheet at baseline and after a period of nine months. Randomized placebo controlled double blind design was used to assign participants in respective groups. Participants were randomly assigned to receive 9-month course of either metformin (1500 mg/day) or placebo. Both groups were advised regarding schedule of lifestyle modification. Outcome variables were clinical manifestations related to metabolic, reproductive and androgenic status of PCOS. Results: Out of 80 enrolled PCOS cases, 49 completed the study (metformin=26, placebo=23). The mean age of the study participants of metformin and placebo groups was 23.52±5.18 and 22.09±3.58 years respectively (p=0.262). Menstrual cycle significantly improved in both the study groups (before vs. after - metformin: 19.2% vs. 76.9%, p=0.003; placebo: 19.2% vs. 47.8%, p=0.02) after 9 months, but compared to placebo group no such significant (p=0.12) improvement occurred in metformin group. Severity of hirsutism, presence of acne, serum progesterone level and ovulatory status improved significantly in both groups after completion of the study. Except acanthosis nigricans, other metabolic manifestations did not significantly improve in metformin compared to placebo group after the intervention. While comparing the percentage changes, body mass index (BMI) and waist circumference (WC) reduced significantly in metformin than placebo group (BMI in kg/m2- metformin vs. placebo: -3.63±8.22 vs. +1.42±6.67, p= 0.024; WC in cm - 2.81±7.74 vs. +1.68±7.89, p= 0.05). No significant adverse event was observed in metformin group. Conclusion: Metformin, in conjunction with lifestyle modifications, has favorable impacts on clinical manifestations of PCOS. Ibrahim Med. Coll. J. 2021; 15(2): 1-12

27 January 2025 in Journal of the ASEAN Federation of Endocrine Societies
Verified
Journal Article
Open access
PDF file
ECEmran-Ur-Rashid Chowdhury
Emran-Ur-Rashid Chowdhury
HBHurjahan Banu
Hurjahan Banu
Md Shahed-MorshedMd Shahed-Morshed
Md Shahed-Morshed
IJIffat Ara Jahan
Iffat Ara Jahan
SKSubi Kharel
Subi Kharel
MHMuhammad Abul Hasanat
Muhammad Abul Hasanat
Background. Bisphenol A (BPA) is a widely used industrial element. Recently it is suspected that BPA may disrupt the endocrine system to influence the manifestations of polycystic ovary syndrome (PCOS). Objective. This study aimed to assess serum BPA level and its association with manifestations of PCOS in women. Methodology. This cross-sectional study included 40 young adults with PCOS and 38 age-matched control women [23.0 (20.0, 29.0) vs. 25.0 (21.0, 29.0), years, median (IQR), p = 0.406]. After a thorough clinical examination, fasting blood was collected in the follicular phase of the menstrual cycle to measure glucose, lipids, insulin, luteinizing hormone, follicle-stimulating hormone, total testosterone, sex hormone binding globulin, dehydroepiandrosterone sulfate, and BPA. Glucose was measured by glucose oxidase, lipids by glycerol phosphate dehydrogenase-peroxidase, all hormones including SHBG by chemiluminescent immunoassay and BPA by sandwiched enzyme-linked immunosorbent assay. Insulin resistance was measured using homeostasis model assessment of insulin resistance. Result. Women with PCOS had significantly higher BPA levels (ng/mL) than the control group [27.30 (25.60, 33.40) vs. 24.0 (15.58, 28.70), median (IQR), p = 0.001]. Using the 75th percentile value of the control group, 15 (37.5%) women with PCOS had high BPA levels. Those with high BPA levels had a significantly higher frequency of menstrual regulation /abortion among women with PCOS [53.8% vs. 0%, p=0.005]. Women with PCOS with a history of menstrual regulation / abortion [36.7 ± 4.9 vs. 28.5 ± 6.4, mean ± SD, p = 0.004] and subfertility [34.3 ± 6.8 vs. 28.5 ± 6.4, mean ± SD, p = 0.031] had higher levels of BPA than those without the histories. Serum BPA had no significant association or correlation with any androgenic and metabolic manifestations. Conclusion. Raised BPA level may be associated with adverse reproductive features in PCOS.

1 September 2023 in Clinical and Experimental Reproductive Medicine
Verified
Journal Article
Open access
PDF file
SAShazia Afrine
Shazia Afrine
JHJasmine Ara Haque
Jasmine Ara Haque
Md Shahed-MorshedMd Shahed-Morshed
Md Shahed-Morshed
HBHurjahan Banu
Hurjahan Banu
AHAhmed Hossain
Ahmed Hossain
MHMuhammad Abul Hasanat
Muhammad Abul Hasanat
Polycystic ovary (PCO), a diagnostic component of polycystic ovary syndrome (PCOS), requires either an ovarian volume (OV) criterion or a follicle number per ovary (FNPO) criterion. This study investigated the association of OV and FNPO criteria with various manifestations of PCOS. This cross-sectional study was conducted at a university hospital among 100 patients newly diagnosed with PCOS (according to the revised Rotterdam criteria). Fasting blood samples were collected to measure glucose, total testosterone (TT), luteinizing hormone (LH), follicle-stimulating hormone (FSH), lipid, insulin, and hemoglobin A1c levels. An oral glucose tolerance test was performed. Transabdominal or transvaginal ultrasound of the ovaries was done, depending on patients' marital status. All investigations were conducted in the follicular phase of the menstrual cycle. OV >10 mL and/or FNPO ≥12 indicated PCO. A homeostasis model assessment of insulin resistance (IR) value ≥2.6 indicated IR, and metabolic syndrome (MS) was defined according to the international harmonization criteria. Seventy-six participants fulfilled the OV criterion, 70 fulfilled the FNPO criterion, and 89 overall had PCO. Both maximum OV and mean OV had a significant correlation with TT levels (r=0.239, p=0.017 and r=0.280, p=0.005, respectively) and the LH/FSH ratio (r=0.212, p=0.034 and r=0.200, p=0.047, respectively). Mean OV also had a significant correlation with fasting insulin levels (r=0.210, p=0.036). Multivariate binary logistic regression analysis showed that IR (odds ratio [OR], 9.429; 95% confidence interval [CI], 1.701 to 52.271; p=0.010) and MS (OR, 7.952; 95% CI, 1.821 to 34.731; p=0.006) had significant predictive associations with OV alone, even after adjustment for age and body mass index. OV may be more closely related to the androgenic and metabolic characteristics of PCOS than FNPO.